Pcn140 Cost-Effectiveness of Nivolumab in Combination With Ipilimumab Compared to Sunitinib for the First-Line Treatment of Advanced/Metastatic Intermediate- Or Poor-Risk Renal Cell Carcinoma in Switzerland

Abstract

when compared to salvage chemotherapy, blinatumomab and inotuzumab, respectively. However, if CAR T-cells are used as a subsequent relapse treatment, its maximum reimbursable prices decreased substantially. CAR T-cell therapy has no therapeutic headroom compared to bone marrow transplant. Conclusions: Maximum reimbursable price of CAR T-cell therapy depends on willingness to pay values, treatment comparator, and sequence of treatments. Early economic evaluation can determine which factors of treatment can impact the costeffectiveness of new interventions.

Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland

“…In 2019, the cost-effectiveness of NIVO + IPI in Switzerland was assessed based on an 18-month database lock [ 39 ]. In this analysis, NIVO + IPI was associated with a higher total number of QALYs versus SUN (increment of 1.27 QALYs) at an increased total cost (increment of CHF97,720), with a corresponding ICUR of CHF77,313/QALY versus SUN.…”

“…Our study provides an updated cost-effectiveness analysis using a more recent 42-month database lock, with the addition of PAZ as a second comparator. Compared with the previous analysis, the new database lock resulted in a higher incremental QALY gain for NIVO + IPI due to more accurate long-term PFS and OS estimates [ 39 ]. However, estimated costs were also substantially higher, which was driven mainly by the application of a more conservative maximum treatment duration.…”

“…However, estimated costs were also substantially higher, which was driven mainly by the application of a more conservative maximum treatment duration. In the previous analysis, all patients were assumed to stop treatment after 24 months, whereas in this analysis, an alternative rule was explored where only patients with a CR stopped treatment 3 months post-CR [ 39 ]. This assumption was informed by the literature [ 13 ] as well as Swiss medical expert input.…”